somatuline depot  (Ipsen Group)

Journal: Chemical Reviews

Article Title: Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications

doi: 10.1021/acs.chemrev.4c00989

Figure Lengend Snippet: On the top is the sequence of the native somatostatin peptide. The blue sequence in somatostatin represents a key pharmacophore in somatostatin, responsible for receptor binding. In somatostatin analogues, lysine (K) is conserved, while tryptophan is replaced with its stereoisomers in octreotide, lanreotide, vapreotide, and pasireotide. Phenylalanine is substituted with tyrosine, which has an additional hydroxyl group, and threonine is replaced with a more hydrophobic amino acid, such as valine, in lanreotide and vapreotide. Pasireotide incorporates the highest number of unnatural amino acids. In this analogue, cyclization occurs between the N- and C-terminal ends, while in octreotide, lanreotide, and vapreotide, cyclization involves the side chains of cysteine residues, similar to native somatostatin.

Article Snippet: lanreotide , Somatuline depot , somatostatin analogue (SSA) , 2007 , Ipsen , acromegaly, neuroendocrine tumors, and conditions with excess hormone secretion , SC.

Techniques: Sequencing, Binding Assay, Analogues

Journal: Pharmaceutics

Article Title: Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance

doi: 10.3390/pharmaceutics17010021

Figure Lengend Snippet: Pharmacokinetic profile (mean drug concentrations + SD) after a single application of prolonged-release lanreotide 90 mg (Somatuline Autogel ® ) in healthy volunteers (n = 13). The X-axis and Y-axis are segmented to show the profile of the product in the initial phase (Days 0–28). pAUC 0–7days , pAUC 7–28days , and pAUC 28-t are highlighted. Insert represents the full profile without axis scaling (adapted from ).

Article Snippet: Lanreotide is a somatostatin analog formulated as an LAI product, administered via deep SC injection every 28 days (Somatuline ® depot, Ipsen Pharma SAS, and Somatuline ® Autogel, Ipsen Ltd., London, UK), used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors [ ].

Techniques:

Journal: Pharmaceutics

Article Title: Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance

doi: 10.3390/pharmaceutics17010021

Figure Lengend Snippet: Mean pAUCs (±SD) and intersubject variability (%) after a single application of prolonged-release lanreotide 90mg (Somatuline Autogel ® ) (n = 10). Data from [ 47 ].

Article Snippet: Lanreotide is a somatostatin analog formulated as an LAI product, administered via deep SC injection every 28 days (Somatuline ® depot, Ipsen Pharma SAS, and Somatuline ® Autogel, Ipsen Ltd., London, UK), used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors [ ].

Techniques:

Journal: Drug Delivery and Translational Research

Article Title: Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies

doi: 10.1007/s13346-024-01747-y

Figure Lengend Snippet: List of marketed microsphere-based long-acting injectables

Article Snippet: Somatuline Depot 60 mg , Ipsen , Lanreotide acetate , Acromegaly , 4 weeks , Spray drying , PLGA.

Techniques: Encapsulation, Polymer, Emulsion, Solvent, Evaporation

Journal: Supportive Care in Cancer

Article Title: PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK

doi: 10.1007/s00520-024-08377-7

Figure Lengend Snippet: Preference for LAN administration setting . Survey population ( N = 80 with five missing values). Whiskers represent 95% confidence intervals. LAN, lanreotide autogel

Article Snippet: Somatuline® (lanreotide) Autogel®/Depot (Ipsen) (herein referred to as LAN) is a long-acting somatostatin analogue indicated for the treatment of functional symptoms associated with NETs.

Techniques:

Journal: Supportive Care in Cancer

Article Title: PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK

doi: 10.1007/s00520-024-08377-7

Figure Lengend Snippet: Impact on activities of daily living with LAN administration at home versus hospital: integrated results from survey and interview populations . LAN, lanreotide autogel

Article Snippet: Somatuline® (lanreotide) Autogel®/Depot (Ipsen) (herein referred to as LAN) is a long-acting somatostatin analogue indicated for the treatment of functional symptoms associated with NETs.

Techniques:

Journal: Advances in Therapy

Article Title: PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly

doi: 10.1007/s12325-022-02360-6

Figure Lengend Snippet: Patient disposition. a All participants from the screened population who met the inclusion/exclusion criteria and started to complete the survey. b All enrolled participants who completed the survey with no data quality concerns and irrespective of whether they had NETs or acromegaly; c 132 patients (97.1%) had received the branded formulation, and 4 patients (2.9%) had received the generic formulation. d Participants with at least 6 months’ experience of their current SSA treatment; e 122 participants (96.8%) had received the branded formulation, and 4 participants had received (3.2%) the generic formulation. f Participants who had been treated with both LAN and OCT. g All participants received the branded formulation. h Excluded participants from the USA as independent injection of lanreotide autogel is not approved in the USA. LAN lanreotide autogel/depot, NET neuroendocrine tumor, OCT octreotide long-acting release

Article Snippet: There are currently two proprietary (branded) injectable LA SSAs available for first-line treatment of NETs and acromegaly: Somatuline® (lanreotide) Autogel/Depot (Ipsen)—herein referred to as LAN—and Sandostatin® (octreotide) Long-Acting Release (Novartis)—herein referred to as OCT. LAN is provided as a ready-to-use prefilled syringe for administration by deep subcutaneous injection once every 28 days [ , ].

Techniques: Formulation, Injection

Journal: Advances in Therapy

Article Title: PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly

doi: 10.1007/s12325-022-02360-6

Figure Lengend Snippet: Proportion of patients with pain at injection site lasting > 2 days after most recent injection (Survey population a ). a All participants who completed the survey with no data quality concerns and irrespective of whether they had NETs or acromegaly. CI confidence interval, LAN lanreotide autogel/depot, NET neuroendocrine tumor, OCT octreotide long-acting release

Article Snippet: There are currently two proprietary (branded) injectable LA SSAs available for first-line treatment of NETs and acromegaly: Somatuline® (lanreotide) Autogel/Depot (Ipsen)—herein referred to as LAN—and Sandostatin® (octreotide) Long-Acting Release (Novartis)—herein referred to as OCT. LAN is provided as a ready-to-use prefilled syringe for administration by deep subcutaneous injection once every 28 days [ , ].

Techniques: Injection

Journal: Advances in Therapy

Article Title: PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly

doi: 10.1007/s12325-022-02360-6

Figure Lengend Snippet: Injection-site pain ( a ), injection-related issues ( b ) and technical injection problems ( c , d ) associated with LA SSA injection (Overall experience population a ). a Participants with at least 6 months’ experience with their current SSA treatment. b Participants were asked which symptoms/problems they had experienced—data are for those who experienced at least one issue (note that participants could choose more than one issue). c In participants who experienced technical problems (36 participants in the LAN group and 72 in the OCT group). CI confidence interval, LA long-acting, LAN lanreotide autogel/depot, OCT octreotide long-acting release, SSA somatostatin analog

Article Snippet: There are currently two proprietary (branded) injectable LA SSAs available for first-line treatment of NETs and acromegaly: Somatuline® (lanreotide) Autogel/Depot (Ipsen)—herein referred to as LAN—and Sandostatin® (octreotide) Long-Acting Release (Novartis)—herein referred to as OCT. LAN is provided as a ready-to-use prefilled syringe for administration by deep subcutaneous injection once every 28 days [ , ].

Techniques: Injection

Journal: Advances in Therapy

Article Title: PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly

doi: 10.1007/s12325-022-02360-6

Figure Lengend Snippet:

Article Snippet: There are currently two proprietary (branded) injectable LA SSAs available for first-line treatment of NETs and acromegaly: Somatuline® (lanreotide) Autogel/Depot (Ipsen)—herein referred to as LAN—and Sandostatin® (octreotide) Long-Acting Release (Novartis)—herein referred to as OCT. LAN is provided as a ready-to-use prefilled syringe for administration by deep subcutaneous injection once every 28 days [ , ].

Techniques: Analogues, Injection